Osterweis Capital Management Inc. Acquires 11,080 Shares of Repligen Corporation $RGEN

Key Points

• Osterweis Capital Management Inc. increased its holdings in Repligen Corporation by 18% in Q1, owning 72,765 shares valued at approximately $9.26 million.
• Repligen's stock has a current market cap of $6.72 billion with revenue growth of 14.8% year-over-year, despite a recent earnings miss.
• Analyst ratings show a consensus of "Moderate Buy" with an average price target of $169.55 after several recent upgrades to buy ratings from various analysts.

Osterweis Capital Management Inc. increased its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 18.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 72,765 shares of the biotechnology company's stock after purchasing an additional 11,080 shares during the quarter. Osterweis Capital Management Inc. owned 0.13% of Repligen worth $9,259,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. KBC Group NV lifted its position in Repligen by 14.9% in the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 329 shares during the period. Harvest Fund Management Co. Ltd bought a new position in Repligen during the first quarter valued at about $132,000. XTX Topco Ltd raised its position in Repligen by 34.2% in the first quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock worth $1,646,000 after acquiring an additional 3,295 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Repligen by 40.1% in the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 274 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd lifted its stake in Repligen by 233.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company's stock valued at $1,172,000 after purchasing an additional 6,448 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Transactions at Repligen

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Evercore ISI lowered their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Wells Fargo & Company decreased their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Jefferies Financial Group decreased their price target on shares of Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a report on Friday, September 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Wednesday, September 3rd. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and a consensus target price of $166.67.

Repligen Stock Down 0.6%

Shares of RGEN traded down $0.75 on Wednesday, hitting $119.01. The company's stock had a trading volume of 373,757 shares, compared to its average volume of 774,610. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $6.70 billion, a price-to-earnings ratio of -475.44, a P/E/G ratio of 2.10 and a beta of 1.07. The firm's fifty day moving average price is $120.34 and its 200-day moving average price is $127.21. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm's quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities research analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.